This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
ACTB / Actin, cytoplasmic 1 · IHC design guide
Design Immunohistochemistry for ACTB
Plan chromogenic ACTB IHC on paraffin sections using high myoepithelial staining as a reference (HPA tissue IHC). This guide covers fixation, detection and interpretation, including the possibility of staining proteins from more than one gene (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
ACTB Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic cytoskeleton; nuclear ACTB also annotated (UniProt) | |
| Staining pattern | High in myoepithelial cells; compartment unreported (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet M01263-3) | |
| Positive control | Appendix+4 more · see all | |
| Negative control | Adrenal gland+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image M01263-3) | |
| Caveat | Antibodies may detect proteins from more than one gene (HPA tissue IHC) | |
| Regulation | No intensity regulator established (UniProt) | |
| Isoform / epitope | No isoforms; N-terminal processing may affect N-terminal epitopes (UniProt) |
Section 1
Recommended ACTB IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet: M01263-3) is paired with published ACTB IHC methods for human hepatocellular carcinoma (PMC10772687) and paraffin sections (PMC12446288).
| Sample | Formaldehyde-fixed, paraffin-embedded human heart tissue (datasheet M01263-3) |
| Fixation | Image formalin-fixed; duration unreported (datasheet M01263-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6 (datasheet M01263-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Mouse monoclonal (clone 137CT26.1.1) anti-ACTB, 1:25 (datasheet M01263-3) |
| Primary incubation | 1 hours at 37°C (datasheet M01263-3) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | ACTB-positive staining in enterocytes - Microvilli of appendix (HPA tissue IHC: High). HPA tissue profile: High myoepithelial expression in all tissues. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6 (datasheet: M01263-3); one published ACTB protocol used 10 mM citrate for 10 min in a microwave (PMC12446288).
Section 2
What Is the Expected ACTB Staining Pattern?
ACTB is expected mainly in the cytoplasm and cytoskeleton; nuclear signal can also be genuine (UniProt P60709 subcellular location). In IHC, HPA reports high staining in myoepithelial cells and enterocyte microvilli, among other cell types (HPA tissue IHC). The tissue profile is Supported with medium staining–RNA consistency and a warning that the antibodies may target protein from more than one gene (HPA tissue IHC). ACTB has no transmembrane segment (UniProt P60709 topology).
| Cytoplasmic staining in breast myoepithelial cells, with signal following cell outlines. | This fits the reported high myoepithelial staining and ACTB’s cytoskeletal location (HPA tissue IHC; UniProt P60709 subcellular location). Judge the distribution in the named cells; an apparently strong field is less informative if the signal cannot be assigned to them (general IHC practice). |
| Strong staining at the microvilli of appendix, colon, or duodenal enterocytes. | This matches HPA’s high enterocyte microvillar staining in those tissues (HPA tissue IHC). A concentrated apical pattern can therefore be an expected positive result. Use the tissue architecture and counterstain to distinguish a cell-associated edge from stain deposited on the section surface (general IHC practice). |
| Signal confined to extracellular material or an apparent membrane rim, without corresponding cytoplasmic staining. | That distribution is discordant with ACTB’s cytoplasmic/cytoskeletal location and lack of a transmembrane segment (UniProt P60709 subcellular location; topology). Check for staining artefact before scoring it as ACTB. Nuclear staining alone needs separate assessment because UniProt also lists a nuclear location (UniProt P60709 subcellular location). |
| Strong staining only in a cell population reported as not detected, or colour in cells on a no-primary control. | For example, HPA reports no detection in bronchial respiratory epithelium, but that observation is antibody and context dependent (HPA tissue IHC). Unexpected staining raises cross-reactivity or endogenous detection activity; colour on a no-primary control particularly supports a detection-system problem (general IHC practice). |
| Uniform haze across cells, stroma, and empty spaces, or no signal in a known-positive compartment. | A nonanatomic haze obscures cell-level interpretation and suggests background from the staining workflow (general IHC practice). Conversely, absent staining in breast myoepithelial cells or colon enterocyte microvilli conflicts with HPA’s high observations and calls for a run-control review before a negative interpretation (HPA tissue IHC; general IHC practice). |
💡Expected ACTB appearanceCall a convincing positive when cell-associated cytoplasmic/cytoskeletal staining is strong in breast myoepithelial cells or enterocyte microvilli (HPA tissue IHC; UniProt P60709 subcellular location); isolated extracellular colour or colour on a no-primary control is suspect (general IHC practice).
| Tissue and cell selection | HPA reports high signal in breast myoepithelial cells, placental endothelium, and enterocyte microvilli, but low signal in lung macrophages and heart cardiomyocytes (HPA tissue IHC). Choose a control by its named cell population; low or undetected populations provide weaker evidence that a run worked. |
| Specificity of the observed pattern | HPA rates tissue IHC Supported, describes medium consistency with RNA, and cautions that the antibodies may target protein from more than one gene (HPA tissue IHC). A matching pattern supports interpretation but does not, by itself, establish molecular specificity. The listed antibodies have IHC Supported status; ICC status is unreported (HPA antibodies). |
| Topology and processing | ACTB lacks a transmembrane segment and signal peptide, and UniProt lists cytoplasmic/cytoskeletal and nuclear locations (UniProt P60709 topology; processing; subcellular location). Interpret a purely extracellular or membrane-only pattern cautiously. UniProt lists full-length and N-terminally processed chains; the supplied record gives no antibody epitope, so it cannot predict which chain is detected (UniProt P60709 processing). |
| Antigen retrieval and fixation | No target-specific fixation sensitivity or retrieval condition is established by the supplied UniProt or HPA records. Retrieval is an IHC workflow variable to check against the IHC-validated antibody’s instructions and run controls (general IHC practice); HPA staining levels cannot be used to infer an ACTB-specific fixation effect. |
| IF/ICC question: can the IHC pattern be carried over? | UniProt lists cytoplasmic/cytoskeletal and nuclear ACTB (UniProt P60709 subcellular location). HPA supplies no main ICC-IF location or cell-line images, and the listed antibodies have no ICC validation status (HPA subcellular; HPA antibodies). Those records do not establish an IF/ICC staining pattern or protocol. |
| Situation | Likely cause | Next action |
|---|---|---|
| No stain in breast myoepithelial cells or colon enterocyte microvilli. | These are reported high IHC compartments, so their absence may indicate a failed staining run or an unsuitable control section (HPA tissue IHC; general IHC practice). | Confirm that the named cells are present, then review the IHC-validated antibody and detection controls, retrieval record, and reagent application before scoring the sample negative (general IHC practice). |
| Only weak signal in lung macrophages or heart cardiomyocytes. | HPA reports low staining in those cell types (HPA tissue IHC). Weak signal there alone does not show that the assay failed. | Compare with a reported high cell population on an appropriate control section, such as breast myoepithelial cells, before adjusting the workflow (HPA tissue IHC; general IHC practice). |
| Diffuse brown haze hides cell boundaries. | Background can arise from the detection workflow or insufficient blocking or washing (general IHC practice); the haze has no interpretable ACTB compartment. | Examine a no-primary control, review blocking and wash steps, and score only staining that can be assigned to cells and tissue structures (general IHC practice). |
| Colour appears in an unexpected cell type and on a no-primary control. | Signal without primary antibody points to endogenous detection activity or detection-reagent background (general IHC practice). HPA’s cross-gene targeting caution also limits specificity claims from unexpected staining (HPA tissue IHC). | Address the detection-system background and repeat the controls before attributing the cell-specific signal to ACTB (general IHC practice). |
| Apparent membrane-only or extracellular staining dominates the section. | That pattern conflicts with the listed cytoplasmic/cytoskeletal location and absence of a transmembrane segment (UniProt P60709 subcellular location; topology). | Inspect section morphology and controls for deposited stain or edge artefact; seek a cell-associated cytoplasmic pattern before calling it positive (general IHC practice). |
| A nuclear signal is present alongside cytoplasmic staining. | UniProt lists a nuclear location, so nuclear colour is not automatically discordant (UniProt P60709 subcellular location). HPA’s supplied ICC-IF record offers no image-based location check (HPA subcellular). | Check whether nuclear signal follows intact cells and is absent from the no-primary control; report it separately from the HPA tissue IHC pattern (general IHC practice; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing ACTB staining
M01263-3 · IHCM01263-3 staining ACTB in human heart tissue sections by Immunohistochemistry (IHC-P -paraformaldehyde-fixed, paraffin-embedded sections). T
M01263-3 · IHCImmunohistochemical analysis of paraffin-embedded H.skeletal muscle section using Beta-Actin Antibody. M01263-3 was diluted at 1:25 dilution
M01263-3 · IFConfocal immunofluorescent analysis of ACTB Antibody with Hela cell followed by Alexa Fluor® 488-conjugated goat anti-mouse lgG (green). DAP
M01263 · IHCImmunohistochemical analysis of paraffin-embedded (1) Human heart; (2) Mouse testis; (3) Human bladder cancer; (4) Mouse heart, using beta A
M01263 · IFImmunofluorescent analysis using the Antibody at 1:50 dilution.
M01263-4 · IHCImmunohistochemical analysis of paraffin-embedded human heart, using beta Actin Mouse Monoclonal Antibody.
M01263-4 · IFImmunofluorescent analysis of HepG2 cells, using beta Actin mAb.
M01263-8 · IHCHuman colon was stained with anti-β Actin rabbit antibody
A01263-1 · IFImmunocytochemistry of beta-actin in HeLa cells with beta-actin antibody at 10 μg/mL.
A01263-2 · IFImmunocytochemistry of Actin in HeLa cells with Actin antibody at 1 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000075624-ACTB/tissue/cerebral+cortex#imid_12522665
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000075624-ACTB/tissue/colon#imid_12526415
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000075624-ACTB/tissue/liver#imid_12526408
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000075624-ACTB/tissue/kidney#imid_12526425
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for ACTB IHC & IF
🧪Run colon first and confirm staining in enterocyte microvilli (HPA: High in colon enterocyte microvilli). Use adrenal gland glandular cells as the HPA-listed negative comparison (HPA: Not detected in adrenal gland glandular cells); on the colon slide, treat unstained areas outside the microvilli as background references, not proven ACTB-negative cells.
Positive control tissue: Appendix (Enterocytes - Microvilli, HPA High)
Negative control tissue: Adrenal gland (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for ACTB; derive a cell-line control from the positive tissue's cell type (Enterocytes - Microvilli) and confirm it by RNA or western blot first.
Technical controls: Include no-primary (secondary-only) and host-species- and antibody-class-matched isotype or nonimmune IgG controls; confirm specificity with an ACTB knockout specimen, or a peptide-block control if the immunizing peptide is available (standard IHC practice). For colon chromogenic IHC, quench endogenous peroxidase and check endogenous biotin because the reported secondary is biotinylated (caption: biotinylated secondary antibody).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the selected-SKU fixative is unreported (selected-SKU fixative field: not stated). The paraffin-section example uses heat-mediated citrate retrieval at pH 6, but does not establish that retrieval is required for ACTB (caption: citrate buffer pH6 retrieval). Whether frozen sections or IF/ICC are easier is unreported; inspect colon microvillar staining alongside background controls because that is the proposed positive compartment (HPA: High in colon enterocyte microvilli).
HPA tissue IHC evidence for ACTB
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Appendix | Enterocytes - Microvilli | High | Protein (IHC) | HPA → |
| Breast | Myoepithelial cells | High | Protein (IHC) | HPA → |
| Colon | Enterocytes - Microvilli | High | Protein (IHC) | HPA → |
| Duodenum | Enterocytes - Microvilli | High | Protein (IHC) | HPA → |
| Epididymis | Glandular cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Caudate | Glial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Cerebral cortex | Glial cells | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced ACTB IHC Tips
Troubleshoot ACTB staining in paraffin sections by checking retrieval, cell type, compartment and controls before interpreting intensity.
Which retrieval conditions should I try first for weak ACTB staining?
Start with heat mediated citrate retrieval at pH 6 for ACTB IHC in paraffin sections (datasheet M01263-3). Apply the same heating and cooling conditions to every section in a comparison, then assess signal in intact cells and tissue morphology together (standard IHC practice). The selected image used a primary dilution of 1:25 for 1 hour at 37°C; treat that as a tested image condition, not proof that retrieval alone determines intensity (caption M01263-3). If staining remains weak, vary heating duration on adjacent sections before trying another retrieval buffer, with matched negative controls (standard IHC practice).
How should I troubleshoot variable ACTB staining after fixation?
Target specific sensitivity of ACTB staining to fixation is unknown from the supplied evidence, so establish fixation conditions empirically on comparable paraffin sections (standard IHC practice). Record fixative, time to fixation and fixation duration for each specimen, then keep processing and citrate retrieval at pH 6 consistent during comparison (datasheet M01263-3; standard IHC practice). Compare intact regions with similar morphology and cell composition, since staining intensity alone cannot identify the source of variation (standard IHC practice). If a change improves signal but damages morphology or increases background, retain the condition that best preserves interpretable cell boundaries (standard IHC practice).
Should ACTB staining be cytoplasmic, nuclear or concentrated at cell borders?
Expect predominantly cytoplasmic cytoskeletal staining, including filament associated signal; ACTB is also annotated in the nucleus (UniProt P60709 localisation and function). Signal near cell borders can reflect cortical actin, so assess it alongside cytoplasmic staining and cell morphology before calling it membranous (UniProt P60709 function; standard IHC practice). ACTB has no transmembrane segment, making an exclusively sharp membrane outline a reason to check antibody specificity and detection background (UniProt P60709 topology; standard IHC practice). Compare the pattern with expected cells, such as strongly stained myoepithelial cells, rather than requiring equal intensity across all tissue compartments (HPA: high myoepithelial expression).
Can this stain distinguish ACTB from related actins or processed ACTB?
Do not assign a stained filament specifically to ACTB from morphology alone: the supplied tissue resource cautions that its staining targets protein from more than one gene (HPA: Supported reliability description). The ACTB record lists 0 annotated isoforms but describes both an intact 1–375 chain and an N terminally processed 2–375 chain (UniProt P60709 processing and isoforms). It also lists N terminal acetylation and modifications at residues 44, 47 and 73, without locating this antibody's epitope (UniProt P60709 modified residues; supplied antibody evidence). Confirm sequence level specificity and epitope accessibility using antibody documentation or orthogonal controls before interpreting selective staining (standard IHC practice).
How should I assess ACTB in a multiplex IF experiment?
For a separate IF experiment, pair ACTB with a validated marker of the expected cell type, such as myoepithelial cells, and assess overlap at single cell resolution (HPA: high myoepithelial expression; standard IF practice). Choose a spectrally separated fluorophore, preferably in a far red channel when the tissue shows strong shorter wavelength autofluorescence, and inspect unstained and single stain controls (standard IF practice). Because ACTB is cytoplasmic and can also be nuclear, test mild permeabilisation appropriate to an intracellular epitope rather than assuming surface access (UniProt P60709 localisation and topology; standard IF practice). The supplied selected antibody evidence is an IHC image, so establish IF staining performance independently (caption M01263-3).
What should I check when ACTB IHC shows diffuse brown background?
Run a no primary control and inspect whether brown deposit follows tissue structures or appears in damaged regions, vessels or section edges (standard chromogenic IHC practice). Quench endogenous peroxidase before DAB development and compare development times across matched sections; these are general detection controls, not ACTB specific findings (standard chromogenic IHC practice). The selected image used 3% BSA for 30 minutes and a biotinylated secondary, so assess nonspecific binding and endogenous biotin if following that detection scheme (caption M01263-3; standard IHC practice). Titrate the primary around the image condition of 1:25 while preserving a clearly structured cellular pattern (caption M01263-3; standard IHC practice).
How can I score ACTB staining across heterogeneous paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell type and compartment before scoring, because ACTB is cytoplasmic and nuclear and tissue staining varies by cell population (UniProt P60709 localisation; HPA tissue IHC). For chromogenic sections, record the percentage of positive viable cells and intensity categories, or calculate an H score from 0–300 using the same thresholds throughout (standard IHC scoring practice). If counting stained cells, report density per mm² of viable, annotated tissue and retain the sampled area for each section (standard image analysis practice). Normalise comparisons to the number of eligible cells or viable area within the same cell population, rather than to whole section darkness (standard IHC scoring practice).
How do I separate true ACTB signal from staining artefact?
A convincing result has cellular structure consistent with cytoplasmic cytoskeleton, while nuclear ACTB is also biologically plausible and needs compartment specific controls (UniProt P60709 localisation and function; standard IHC practice). Check the expected cell population: myoepithelial cells and enterocyte microvilli show high staining in the supplied tissue resource, whereas cardiomyocytes are listed as low (HPA tissue IHC). Abruptly stronger section edges, necrotic areas and signal in no primary controls point to processing or detection artefact (standard IHC practice). If brown staining persists without primary antibody, review endogenous peroxidase and, when using the selected biotinylated secondary, endogenous biotin before assigning ACTB expression (caption M01263-3; standard IHC practice).
Boster reagents
Best ACTB / Actin, cytoplasmic 1 IHC Antibodies
Six anti-ACTB antibodies have IHC images from human or mouse tissues, or IF/ICC images from HeLa cells (catalog image captions); all list human reactivity (catalog reactivity).
Real IHC data
Anti-Beta-Actin Antibody
Cat # M01263-3
Real IHC data
Anti-beta Actin ACTB Rabbit Monoclonal Antibody
Cat # M01263
Real IHC data
Anti-beta Actin Mouse Monoclonal Antibody
Cat # M01263-4
Real IHC data
Anti-β Actin Rabbit Monoclonal Antibody
Cat # M01263-8
Real IF data
Anti-Beta-actin ACTB Antibody
Cat # A01263-1
Real IF data
Anti-beta-Actin ACTB Antibody
Cat # A01263-2
M01263-3 shows human heart IHC-P; M01263 shows IHC in human heart, human bladder cancer, mouse testis and mouse heart; M01263-4 shows human heart IHC; and M01263-8 shows human colon staining (catalog IHC image captions). A01263-1 and A01263-2 show HeLa cell ICC/IF images, while both list IF among their applications (catalog image captions and applications).
Which to pick: For tissue IHC-P, choose M01263-3 when its documented formaldehyde fixation and citrate pH 6 retrieval suit the experiment (M01263-3 IHC image caption). For HeLa cell IF/ICC, consider A01263-1, which lists both applications and has corresponding images; A01263-2 has HeLa ICC/IF images and lists IF (catalog applications and image captions). For the broadest listed species coverage, choose M01263-4, a mouse monoclonal reactive with chicken, human, mouse, pig, rabbit and rat; its IHC image shows a paraffin-embedded human heart section, with fixative unreported (catalog host, reactivity and IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P60709 (ACTB_HUMAN, Actin, cytoplasmic 1).
- Human Protein Atlas. ACTB tissue IHC expression (reliability: Supported).
- Human Protein Atlas. ACTB subcellular location (ICC-IF): Highest expression in PODO/TERT256: 12477.8 nTPM.
- Human Protein Atlas. ACTB antibody validation summary (3 antibodies).
- Differential tumor protein expression at follicular lymphoma diagnosis reveals dysregulation of key molecular pathways associated with histological transformation. Scientific reports 2024 — PMC11612490.
- ACTB may serve as a predictive marker for the efficacy of lenvatinib in patients with HBV-related early-stage hepatocellular carcinoma following partial hepatectomy: a retrospective cohort study. Journal of gastrointestinal oncology 2023 — PMC10772687.
- Exploring heterogeneous expression of beta-actin (ACTB) in bladder cancer by producing a monoclonal antibody 6D6. BMC urology 2024 — PMC11167769.
- Altered actin isoforms expression and enhanced airway responsiveness in asthma: the crucial role of β-cytoplasmic actin. Frontiers in physiology 2025 — PMC12446288.
- PubMed PMID:6322116 — UniProt-cited evidence.
- PubMed PMID:2994062 — UniProt-cited evidence.
- PubMed PMID:1734024 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for ACTB (Actin, cytoplasmic 1). Expected localisation Cytoplasmic cytoskeleton; nuclear ACTB also annotated (UniProt). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet M01263-3). Validated IHC antibody: M01263-3 at 1:25 (the product's own IHC validation image is shown). Controls (HPA): positive Appendix (Enterocytes - Microvilli); negative Adrenal gland. IHC-P workflow on paraffin sections. Protocol steps: 1. Sample: Formaldehyde-fixed, paraffin-embedded human heart tissue (datasheet M01263-3); 2. Fixation: Image formalin-fixed; duration unreported (datasheet M01263-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 (datasheet M01263-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Mouse monoclonal (clone 137CT26.1.1) anti-ACTB, 1:25 (datasheet M01263-3); 9. Primary incubation: 1 hours at 37°C (datasheet M01263-3). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image M01263-3); Caveat: Antibodies may detect proteins from more than one gene (HPA tissue IHC); Isoform / epitope: No isoforms; N-terminal processing may affect N-terminal epitopes (UniProt); Regulation: No intensity regulator established (UniProt). Evidence: UniProt P60709, HPA tissue IHC · Supported, HPA cell-line RNA · Highest expression in PODO/TERT256: 12477.8 nTPM, Datasheet M01263-3, PMC10772687, PMC12446288. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/ACTB/immunohistochemistry-ihc-guide.